Profile of rifaximin and its potential in the treatment of irritable bowel syndrome

References

• BrandtLJCheyWDFoxx-OrensteinAEAn evidence-based position statement on the management of irritable bowel syndromeAm J Gastroenterol2009104Suppl 1S1S3519521341
   PubMed Web of Science ®Google Scholar
• HorwitzBJFisherRSThe irritable bowel syndromeN Engl J Med2001344241846185011407347
   PubMed Web of Science ®Google Scholar
• OldenKWDiagnosis of irritable bowel syndromeGastroenterology200212261701171412016433
   PubMed Web of Science ®Google Scholar
• AgarwalNSpiegelBMThe effect of irritable bowel syndrome on health-related quality of life and health care expendituresGastroenterol Clin North Am2011401111921333898
   PubMed Web of Science ®Google Scholar
• Schwille-KiuntkeJEnckPZendlerCPostinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or CampylobacterNeurogastroenterol Motil20112311e479e48821883703
   PubMed Web of Science ®Google Scholar
• BolinoCMBercikPPathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial roleInfect Dis Clin North Am2010244961975ix20937460
   PubMed Web of Science ®Google Scholar
• EspositoIde LeoneADi GregorioGBreath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibioticsWorld J Gastroenterol200713456016602118023092
   PubMed Web of Science ®Google Scholar
• KassinenAKrogius-KurikkaLMakivuokkoHThe fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjectsGastroenterology20071331243317631127
   PubMed Web of Science ®Google Scholar
• BalsariACeccarelliADubiniFFesceEPoliGThe fecal microbial population in the irritable bowel syndromeMicrobiologica1982531851947121297
   PubMed Web of Science ®Google Scholar
• MalinenERinttilaTKajanderKAnalysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCRAm J Gastroenterol2005100237338215667495
   PubMed Web of Science ®Google Scholar
• RanaSVMalikABreath tests and irritable bowel syndromeWorld J Gastroenterol201420247587760124976698
   PubMed Web of Science ®Google Scholar
• TanaCUmesakiYImaokaAHandaTKanazawaMFukudoSAltered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndromeNeurogastroenterol Motil2010225512519e114e11519903265
   PubMed Web of Science ®Google Scholar
• FordACSpiegelBMTalleyNJMoayyediPSmall intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysisClin Gastroenterol Hepatol20097121279128619602448
   PubMed Web of Science ®Google Scholar
• GhoshalUCSrivastavaDIrritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hypeWorld J Gastroenterol201420102482249124627585
   PubMed Web of Science ®Google Scholar
• MeyratPSafroneevaESchoepferAMRifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 monthsAliment Pharmacol Ther20123611–121084109323066911
   PubMed Web of Science ®Google Scholar
• PimentelMChowEJLinHCNormalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled studyAm J Gastroenterol200398241241912591062
   PubMed Web of Science ®Google Scholar
• PimentelMChatterjeeSChowEJParkSKongYNeomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled studyDig Dis Sci20065181297130116832617
   PubMed Web of Science ®Google Scholar
• FutagamiSItohTSakamotoCSystematic review with meta-analysis: post-infectious functional dyspepsiaAliment Pharmacol Ther201541217718825348873
   PubMed Web of Science ®Google Scholar
• FordACMoayyediPLacyBEAmerican College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipationAm J Gastroenterol2014109Suppl 1S2S26 quiz S725091148
   PubMed Web of Science ®Google Scholar
• BasseriRJWeitsmanSBarlowGMPimentelMAntibiotics for the treatment of irritable bowel syndromeGastroenterol Hepatol201177455493
   Google Scholar
• YangJLeeHRLowKChatterjeeSPimentelMRifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBSDig Dis Sci200853116917417520365
   PubMed Web of Science ®Google Scholar
• ScarpignatoCPelosiniIRifaximin, a poorly absorbed antibiotic: pharmacology and clinical potentialChemotherapy200551Suppl 1366615855748
   PubMed Web of Science ®Google Scholar
• PistikiAGalaniIPylerisEBarbatzasCPimentelMGiamarellos-BourboulisEJIn vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowthInt J Antimicrob Agents201443323624124461710
   PubMed Web of Science ®Google Scholar
• AmentaMDalle NogareERColombaCIntestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infectionsJ Chemother199911539139510632386
   PubMed Web of Science ®Google Scholar
• UmezawaHMizunoSYamazakiHNittaKInhibition of DNA-dependent RNA synthesis by rifamycinsJ Antibiot19682132342364876998
   PubMed Web of Science ®Google Scholar
• RivkinAGimSRifaximin: new therapeutic indication and future directionsClin Ther201133781282721741091
   PubMed Web of Science ®Google Scholar
• LaterzaLIaniroGScoleriIRifaximin for the treatment of diarrhoea-predominant irritable bowel syndromeExpert Opin Pharmacother201516460761525641072
   PubMed Web of Science ®Google Scholar
• DescombeJJDubourgDPicardMPalazziniEPharmacokinetic study of rifaximin after oral administration in healthy volunteersInt J Clin Pharmacol Res199414251567836025
   PubMedGoogle Scholar
• XuDGaoJGillillandM3rdRifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in ratsGastroenterology2014146248449624161699
   PubMed Web of Science ®Google Scholar
• ScheyRRaoSSThe role of rifaximin therapy in patients with irritable bowel syndrome without constipationExpert Rev Gastroenterol Hepatol20115446146421780893
   PubMed Web of Science ®Google Scholar
• BrennerDMMoellerMJCheyWDSchoenfeldPSThe utility of probiotics in the treatment of irritable bowel syndrome: a systematic reviewAm J Gastroenterol2009104410331049 quiz 5019277023
   PubMed Web of Science ®Google Scholar
• GaoJGillillandMG3rdOwyangCRifaximin, gut microbes and mucosal inflammation: unraveling a complex relationshipGut Microbes20145457157525244596
   PubMed Web of Science ®Google Scholar
• BrownELXueQJiangZDXuYDupontHLPretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profilesAntimicrob Agents Chemother201054138839619858255
   PubMed Web of Science ®Google Scholar
• LeeKNLeeOYIntestinal microbiota in pathophysiology and management of irritable bowel syndromeWorld J Gastroenterol201420278886889725083061
   PubMed Web of Science ®Google Scholar
• MencarelliARengaBPalladinoGInhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cellsEur J Pharmacol20116681–231732421806984
   PubMed Web of Science ®Google Scholar
• ShararaAIAounEAbdul-BakiHMounzerRSidaniSElhajjIA randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulenceAm J Gastroenterol2006101232633316454838
   PubMed Web of Science ®Google Scholar
• PimentelMLemboACheyWDRifaximin therapy for patients with irritable bowel syndrome without constipationN Engl J Med20113641223221208106
   PubMed Web of Science ®Google Scholar
• PimentelMChangCChuaKSAntibiotic treatment of constipation-predominant irritable bowel syndromeDig Dis Sci20145961278128524788320
   PubMed Web of Science ®Google Scholar
• PimentelMMoralesWChuaKEffects of rifaximin treatment and retreatment in nonconstipated IBS subjectsDig Dis Sci20115672067207221559740
   PubMed Web of Science ®Google Scholar
• YuDCheesemanFVannerSCombined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBSGut201160333434021112950
   PubMed Web of Science ®Google Scholar
• CottreauJBakerSFDuPontHLGareyKWRifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infectionsExpert Rev Anti Infect Ther20108774776020586560
   PubMed Web of Science ®Google Scholar
• KimerNKragAMollerSBendtsenFGluudLLSystematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathyAliment Pharmacol Ther201440212313224849268
   PubMed Web of Science ®Google Scholar
• GuslandiMRifaximin in the treatment of inflammatory bowel diseaseWorld J Gastroenterol201117424643464622180705
   PubMed Web of Science ®Google Scholar
• MattilaEArkkilaPMattilaPSTarkkaETissariPAnttilaVJRifaximin in the treatment of recurrent Clostridium difficile infectionAliment Pharmacol Ther201337112212823095030
   PubMed Web of Science ®Google Scholar
• PelosiniIScarpignatoCRifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tractChemotherapy200551Suppl 112213015855757
   PubMed Web of Science ®Google Scholar
• SchoenfeldPPimentelMChangLSafety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trialsAliment Pharmacol Ther201439101161116824697851
   PubMed Web of Science ®Google Scholar
• BlandizziCViscomiGCMarzoAScarpignatoCIs generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteersPharmacol Res201485394424836868
   PubMed Web of Science ®Google Scholar
• BoltinDPeretsTTShpornERifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndromeAnn Clin Microbiol Antimicrob2014134925319626
   PubMed Web of Science ®Google Scholar
• HuangEEsrailianESpiegelBMThe cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysisAliment Pharmacol Ther20072681147116117894657
   PubMed Web of Science ®Google Scholar
• PimentelMParkSMirochaJKaneSVKongYThe effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trialAnn Intern Med2006145855756317043337
   PubMed Web of Science ®Google Scholar